Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacific Biosciences of California, Inc. - Common Stock (NQ:PACB)

1.390 -0.100 (-6.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacific Biosciences of California, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Analyst Expectations for Pacific Biosciences's Future
Via Benzinga
Rising Fuel Costs Lead To Win For Energy, Cathie Wood's Biotech Play Loses Big - ETF Winners And Losers: Medium-Cap Returns
We performed a screening of medium-cap ETFs, defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns... 
Via Benzinga
Topics ETFs
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The growth-focused money manager is making moves, with her ETFs beating the market again in 2023 after terrible returns the two previous years. 
Via The Motley Fool
Palantir Post Q2 Earnings Share Price Dip Doesn't Deter Cathie Wood — Ark Invest Buys $14M Worth Of Shares
Via Benzinga
Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports
Via Benzinga
The Latest Analyst Ratings for Pacific Biosciences
Via Benzinga
Analyst Ratings for Pacific Biosciences
Via Benzinga
PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care
Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms 
From GeneDx Holdings Corp.; PacBio
Via GlobeNewswire
Cathie Wood's Ark Invest Acquires $5.5M of Robinhood Shares Following Platform's First Profitable Quarter
Via Benzinga
Thoughts For Thursday: Back From The Holiday With Caution
Caution is perhaps what was reflected in yesterday's back from the holiday trading. One there is the question of upcoming Fed action and second there is the visit of Secretary Yellen to China. 
Via Talk Markets
Where Pacific Biosciences Stands With Analysts
Via Benzinga
Expert Ratings for Pacific Biosciences
Via Benzinga
Pacific Biosciences (NASDAQ: PACB) Making Surprising Moves in Friday Session
Via Investor Brand Network
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023
Via Benzinga
Market Mixes It Up With A Broad Rally
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
Time To Play Small Cap Life Science Stocks
The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling. 
Via Talk Markets
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Earnings Outlook For Pacific Biosciences
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
Via Benzinga
Something Happened In Biotech Last Week
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
Cathie Wood Scoops Up AMD Stock On A Day When It Tanks Over 9%: Also Raises Stake In This Biotech Company
Via Benzinga
Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector
A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro... 
Via Talk Markets
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Biotech And Life Science Trades: Q1 2023 Performance By The Numbers
Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
Via Benzinga
Rumble, TORM And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
SMID Cap Life Science Update: Are You An Investor Or Trader?
Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows. 
Via Talk Markets
Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week
These cutting-edge biotech companies quickly fell out of favor with investors this week. 
Via The Motley Fool
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback